Hook / Thesis
Trip.com Group (NASDAQ: TCOM) has been punished in the market after a regulatory spotlight on alleged monopolistic practices and several follow-on class action filings. The headline-driven drawdown has pushed the stock into deep value territory relative to its own history and, by many measures, versus where it traded earlier this year. At the current price near $49.70, TCOM offers a risk-reward setup where reopening of China's travel economy and improving macro mobility trends should be the primary fundamental tailwind.
My view: this is a tradeable, risk-managed long for investors who accept regulatory headline risk. Market fear is priced in to a large degree - the company trades at a market cap of roughly $34.55 billion and a trailing P/E of 7.45 - and the business still benefits from clear secular demand for travel and accommodation services in China and globally. I outline a concrete trade below with entry, stop, targets and the logic supporting it.
What Trip.com does and why it matters
Trip.com Group is a global one-stop travel platform operating brands like Ctrip, Qunar, Trip.com and Skyscanner. The company sells hotel rooms, airline tickets, packaged tours, corporate travel services, and ad-related services. Its scale in mainland China makes it a bellwether for travel recovery and discretionary mobility: when Chinese outbound and domestic tourism recover, traffic, bookings and advertising monetization all re-rate higher.
Why the market should care now: the company got caught in a regulatory storm - Chinese SAMR opened an antitrust probe that was widely reported on 01/14/2026, and the stock fell sharply on the news. Lawsuits followed, and law firms set lead plaintiff deadlines in May 2026 (05/11/2026). That sequence drove a meaningful and emotional sell-off that looks disproportionate to the near-term earnings impact. At the same time, demand-side indicators for travel in China are intact; the company remains exposed to structural growth in travel consumption as the economy normalizes and consumer mobility increases.
Numbers that matter
- Current price: $49.70.
- Market cap: $34.55 billion.
- Shares outstanding: 696,080,072.
- Trailing P/E: 7.45. Price-to-book: 1.32.
- 52-week range: $48.48 - $78.99. Recent intra-day low printed near the 52-week low region.
- Dividend per share: $0.28 (annual distribution history shown with last ex-date 03/17/2025).
- Technicals: RSI ~35.4 (near oversold), MACD histogram negative with bearish momentum, 10/20/50-day SMAs clustered above current price.
- Shorting activity: short interest rose to ~14,965,298 (settlement 04/30/2026) with days-to-cover ~5.18; intraday short-volume spiked in early–mid May, signaling elevated speculative positioning.
Valuation framing
At a market cap of ~$34.5B and a trailing P/E of 7.45, Trip.com is trading at a depressed multiple for a market leader in travel. The P/E suggests much of the operational upside and any multiple expansion are not currently priced in. The company also carries a modest payout ($0.28 annual) that supports a base return while investors wait for demand to re-accelerate.
Qualitatively, the stock looks priced for a materially worse regulatory outcome or a prolonged hit to booking volumes. If neither occurs and regulatory risk resolves or becomes manageable, valuation could re-rate. Historically (52-week high $78.99), the market has been willing to pay materially more when the narrative was clearer and regulatory overhangs were absent.
Catalysts (what could push the stock higher)
- Regulatory clarity: any official resolution from SAMR that is not punitive would remove the headline premium and restore investor confidence.
- Quarterly results that show resilient revenue and margin performance despite the probe narrative; better-than-feared bookings/ADR (average daily rate) metrics would re-accelerate revaluation.
- Macro/tourism tailwinds: strong domestic holiday travel and a rebound in outbound travel from China would flow through bookings and advertising revenue.
- Share buybacks, higher distributions or other capital-return programs that signal confidence from management could re-rate the stock.
Trade plan (actionable)
I recommend taking a tactical long position at the current market level with a clearly defined stop and target. This is a long-term directional trade intended to capture a re-rating tied to regulatory resolution and ongoing travel recovery.
- Entry price: $49.70 (current market price).
- Stop loss: $46.00 to limit downside risk if the regulatory situation deteriorates or the tourism recovery stalls.
- Target price: $75.00 (this assumes partial re-rating toward the prior multiple and recovery toward the 52-week range).
- Time horizon: long term (180 trading days). I view 180 trading days as sufficient time for regulatory developments to unfold, for next quarterly report(s) to provide fresh earning visibility, and for travel volumes to seasonally improve.
Practical sizing: treat this as a tactical position sized to your risk tolerance given the regulatory uncertainty; position size should be smaller than a core holding until regulatory clarity is achieved.
Risks and counterarguments
There are real and material risks that could keep the stock depressed or push it lower. Below are the main risks and a counterargument to the bullish stance.
- Regulatory risk - SAMR outcomes could be punitive. If the regulator imposes fines, structural remedies, or restrictions on business practices, the revenue and margin profile could be meaningfully impaired. That would justify a lower multiple and hit market cap well below current levels.
- Legal risk - class action exposure. Several law firms have filed or fired notices regarding securities class actions; lead plaintiff deadlines appeared around 05/11/2026. Litigation can be costly, distracting and prolong uncertainty even without material financial damages.
- Sentiment and short pressure. Short interest and recent short-volume spikes show active negative positioning. That can amplify down days and delay a bottom while traders wait for a clearer narrative.
- Macro / travel slowdown. Travel demand is cyclical. If China experiences an economic slowdown or new COVID-like mobility constraints, bookings could weaken and revenue growth would suffer.
- Execution risk. Operational missteps, higher marketing costs to defend share, or poor product execution could keep margins under pressure even if gross bookings recover.
Counterargument
The bear case is that regulatory scrutiny uncovers significant anticompetitive behavior requiring structural fixes that materially reduce Trip.com's pricing power and margins. That would justify a prolonged valuation multiple contraction. This is the main scenario that would invalidate the trade. It is plausible and investors should size positions with that possibility in mind.
What would change my mind
I would reduce or close this position if one of the following occurs: (a) SAMR announces a major punitive outcome that includes operational remedies, (b) the company reports a sustained sequential decline in bookings or margins on its next two quarterly reports, or (c) short interest spikes further with days-to-cover rising meaningfully above current levels, signaling an entrenched negative market consensus.
Conversely, I would add to the position if Trip.com receives a clear, non-punitive resolution from regulators or if quarterly results beat expectations with sequential improvement in bookings and monetization metrics.
Conclusion
Trip.com is not a no-risk trade. Regulatory and legal overhangs are real and deserving of caution. Still, at roughly $49.70, with a market cap near $34.55 billion, a P/E of 7.45 and a travel demand backdrop that should improve, the stock offers a defined risk-reward for long-horizon traders willing to accept headline noise. The trade plan above balances upside potential toward $75.00 with a protective stop at $46.00 over a long-term horizon (180 trading days). Investors should size the position for regulatory uncertainty and watch the catalysts listed above closely.
Key near-term dates to monitor: regulatory communications related to the SAMR probe and upcoming quarterly results. Relevant litigation deadlines clustered in May 2026 (05/11/2026) deserve attention for sentiment impact.